DIA Global Oncology Development 2021

Toshihiko Doi, MD, PhD

Deputy Director / Chief, Experimental Therapeutics, National Cancer Center Hospital East, Japan

Noboru Yamamoto, MD, PhD

Deputy Director, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan

Global Phase I Studies – Looking from Both Sides – the Academic and CRO Perspectives

Johanna Bendell, MD

Chief Development Officer, Director, Drug Development Unit Nashville, Sarah Cannon, United States

First-in-Human Phase 1 Studies in Oncology: The New Challenge for Asian Investigational Sites

Toshio Shimizu, MD, PhD

Professor, Department of New Experimental Therapeutics and Early Phase 1 Drug De, Kansai Medical University Hospital, Japan

Experiences of Global Phase I Studies - Growth and Challenges -

Satoshi Nishioka, MSc

Early Clinical Development Department, Group II, Daiichi Sankyo Co., Ltd., Japan

Global Phase 1 from the Points of Japan Affiliate of US based Company

Tomoko Takami

Director, Oncology Clinical Development, Oncology Science Unit, MSD K.K., Japan